Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,731 A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Primary: Overall Survival (OS): Adjusted Using Inverse Probability Treatment Weighting (IPTW) — 24.63; 25.77 Months — p==0.0088
Phase 2 N=36 AMG 386 and Abiraterone for Advanced Prostate Cancer
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
N/A N=5,506 Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms, Castration-Resistant
Primary: Overall Survival (OS): Inverse Probability Treatment Weighting (IPTW) — 20.6; 22.5 Months
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants
Phase 3 N=1,030 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Prostatic Neoplasms
Primary: Overall Survival (OS) — 19.6; 19.0 Months — p=0.1677
Phase 2 N=46 Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Prostatic Neoplasms
Primary: Time to Prostate-specific Antigen (PSA) Progression — 7.3 Months
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
Phase 2 N=5 LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
Prostate Cancer
Primary: Maximally Tolerated Dose (MTD) (Phase 1b) — NA mg/m^2
Phase 2 N=63 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Prostate Cancer Metastatic
Primary: Percentage of Participants With PSA Response — 39.7; 15.9; 55.6 percentage of participants
Phase 2 N=119 A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders
N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Phase 4 N=423 A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Primary: The Percentage of Evaluable Participants With at Least One Confirmed Seizure as Adjudicated by the Independent Adjudication Committee (IAC) — 1.1 percentage of…
Phase 2 N=388 Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
Metastatic Castration-resistant Prostate Cancer
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort 1, Cohort 2, Cohort 4 and Cohorts 1 and 2 Combined) — 6.0; 3.0; 12.3…
Early Phase 1 N=27 IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells